|
Market Closed -
Nasdaq
16:00:00 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 43.04 USD | -4.01% |
|
-12.86% | +93.35% |
Company Valuation: LB Pharmaceuticals Inc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Market Cap 1 | 563.2 | 1,388 | - | - |
| Change | - | 146.54% | - | - |
| Enterprise Value (EV) 1 | 313 | 1,033 | 882 | 1,388 |
| Change | - | 230.19% | -14.65% | 57.41% |
| P/E | -7.11x | -7.55x | -8.72x | -8.15x |
| PBR | - | - | - | - |
| PEG | 0.1x | -0.1x | 0.6x | -1.17x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / EBIT | -10.3x | -5.63x | -4.53x | -5.35x |
| EV / FCF | -8.88x | -5.91x | -6.02x | -8.57x |
| FCF Yield | -11.3% | -16.9% | -16.6% | -11.7% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -3.13 | -5.704 | -4.938 | -5.28 |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -30.4 | -183.5 | -194.6 | -259.7 |
| Net income 1 | -25.2 | -176.2 | -190.6 | -237.8 |
| Net Debt 1 | -250.2 | -355 | -506.4 | - |
| Reference price 2 | 22.26 | 43.04 | 43.04 | 43.04 |
| Nbr of stocks (in thousands) | 25,299 | 32,259 | - | - |
| Announcement Date | 3/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.55x | - | - | - | 1.39B | |
| 20.35x | 7.16x | 14.38x | 1.46% | 69.18B | |
| 31.96x | 9.24x | 44.57x | 0.04% | 62B | |
| -73.2x | 14.15x | -68.23x | -.--% | 26.19B | |
| 29.82x | 6.33x | 16.44x | -.--% | 25.75B | |
| -14.7x | 5.35x | -6.73x | -.--% | 24.29B | |
| 26.87x | 5.1x | 16.96x | -.--% | 19.84B | |
| 45.45x | 16.69x | 33.86x | 0.33% | 15.65B | |
| -14.9x | 3360.83x | -17.18x | -.--% | 13.88B | |
| 1005.79x | 35.18x | 607.6x | -.--% | 14.09B | |
| Average | 104.99x | 384.45x | 71.30x | 0.2% | 27.23B | |
| Weighted average by Cap. | 62.74x | 181.79x | 42.16x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LBRX Stock
- Valuation LB Pharmaceuticals Inc
Select your edition
All financial news and data tailored to specific country editions
